Read Summary

The combination of chemotherapy and the epidermal-growth-factor receptor (EGFR) antibody cetuximab shortens survival compared with chemotherapy alone in certain patients with colorectal cancer, according to an open-label randomized trial.
Reuters Health Information

Print Friendly, PDF & Email